Add Life Pharma Ltd.
|BSE: 524665||Sector: Health care|
|NSE: N.A.||ISIN Code: INE124C01016|
|BSE 05:30 | 01 Jan||Add Life Pharma Ltd|
|NSE 05:30 | 01 Jan||Add Life Pharma Ltd|
Add Life Pharma Ltd. (ADDLIFEPHARMA) - News Sector
12.45 am | 21 May 2022 | Bloomberg
Metropolis runs more than 3,000 diagnostics centers as well as pathology laboratories in India and Africa
11.33 pm | 20 May 2022 | Business Standard
Market regulator SEBI slapped a fine on Fortis Healthcare subsidiaries on account of fund diversion by erstwhile promoters
11.31 pm | 20 May 2022 | Business Standard
Company says operational performance came amid geopolitical turmoil resulting in supply chain challenges and inflationary pressures
2.33 pm | 20 May 2022 | Business Standard
The stock gained 9 per cent in two days after the pharma company reported better-than-expected revenue growth in March quarter (Q4FY22).
1.08 am | 20 May 2022 | Business Standard
Dr Reddy's Q4 results: The revenue was up 15% to Rs 5,437 crore for the quarter under review
12.55 am | 20 May 2022 | Business Standard
The company's Russian revenue was at Rs 686 crore for Q4FY22, a year-on-year growth of 70%.
9.39 am | 19 May 2022 | Business Standard
Lupin's performance was skewed on revenues front amid US and India posting lower than expected sales while RoW and South Africa saw better than antici...
9.35 pm | 18 May 2022 | Business Standard
The struggle that he went through in setting up a private health care facility in the India of the 1980s is part of folklore
9.25 pm | 18 May 2022 | Business Standard
Dr Lal PathLabs is India's largest diagnostic services player by revenue, with 289 laboratories across the country
9.22 pm | 18 May 2022 | Business Standard
'Cipla has so many capabilities that for anything we need to do, we say we can do it'
9.18 pm | 18 May 2022 | Business Standard
Having consolidated its presence across geographies, the pharma major is looking at acquisitions
3.16 pm | 18 May 2022 | Business Standard
The pharmaceutical giant may witness some impact due to its large exposure of the business to Russia, and CIS regions.
9.52 am | 18 May 2022 | Business Standard
In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from 25.7 p...
1.47 am | 18 May 2022 | Business Standard
Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line
12.42 pm | 17 May 2022 | Business Standard
Analysts at ICICI Securities expect Aurobindo Pharma's adjusted PAT to de-grow 30.4 per cent year-on-year (YoY) to Rs 557.90 crore in the March 2022 q...
1.05 am | 17 May 2022 | Press Trust of India
Revenue from operations rose to Rs 810 crore for the fourth quarter, compared with Rs 744 crore in the year-ago period, the pharmaceutical major said ...
3.01 am | 16 May 2022 | Business Standard
The last two years saw limited physical inspections due to travel restrictions during the pandemic
12.04 am | 14 May 2022 | Business Standard
Uncontrolled LDL-c, which poses a major risk of cardiovascular diseases, lacked proper treatment despite patients' lifestyle changes and use of statin...
2.03 am | 12 May 2022 | Business Standard
Speaking to Business Standard, Samina Hamied, executive vice chairperson, Cipla, says one must invest in research and development (R&D) to feed the co...
11.46 pm | 11 May 2022 | Business Standard
The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said